Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales

Johnson & Johnson (JNJ) surpassed Q2 profit and sales expectations, reporting adjusted EPS of $2.77 and $23.74 billion in sales, primarily fueled by strong demand for its cancer drug Darzalex and robust performance in its medical device business. This strong operational showing, coupled with a reduced estimate for tariff-related costs, prompted J&J to raise its full-year sales forecast by approximately $2 billion to between $93.2 billion and $93.6 billion, and increase its 2025 adjusted EPS guidance.

Analysis

Johnson & Johnson delivered a robust second-quarter performance, exceeding Wall Street expectations on both revenue and earnings. The company reported adjusted earnings of $2.77 per share against a consensus estimate of $2.68, and quarterly sales of $23.74 billion, surpassing the anticipated $22.84 billion. This outperformance was driven by two key segments: the MedTech unit, which saw sales grow 6.1% to $8.5 billion, and the oncology portfolio, where the cancer drug Darzalex generated sales of $3.54 billion, beating estimates of $3.38 billion. Consequently, management has significantly raised its full-year guidance, now projecting sales between $93.2 billion and $93.6 billion, a substantial increase from the prior forecast of $91.0 billion to $91.8 billion. The 2025 adjusted EPS forecast was also lifted to a range of $10.80 to $10.90. This improved outlook is further supported by a reduction in anticipated tariff-related costs for the year, which have been halved from $400 million to $200 million, demonstrating the company's ability to absorb external pressures while improving its financial targets.

Key Decisions for Investors

• The strong top and bottom-line beat, combined with a significant upward revision to both full-year sales and 2025 EPS guidance, supports a bullish thesis on J&J's operational strength and near-term growth prospects.
• Investors should closely monitor the continued sales momentum of the cancer drug Darzalex and growth within the MedTech division, as these are the primary drivers underpinning the company's upgraded financial outlook.
• While the reduction in expected tariff costs is a positive development, the CFO's commentary on the 'fluid environment' for 2026 suggests that trade policy remains a key long-term risk factor to watch.